Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5345221 | 0.91 | — | — | |
| SCHEMBL1276399 | 0.86 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL1774594 | 0.85 | ALDH1A1 (0.32) | ALDH1A1 | |
| Citric Acid SCHEMBL5049922 | 0.85 | ALDH1A1 (0.43) | ALDH1A1 | |
| Demannose SCHEMBL6062262 | 0.82 | ALDH1A1 (0.38) | ALDH1A1 | |
| Citric Acid SCHEMBL1774082 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL290076 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL14423955 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL2226410 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 | |
| Citric Acid SCHEMBL1774116 | 0.82 | ALDH1A1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360687-A1 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF | L'OREAL (FR) | 2017-12-21 | — | — | US | claimed |
| EP-3236922-A1 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF | L'OREAL (FR) | 2017-11-01 | — | — | EP | claimed |
| WO-2016102702-A1 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| US-20070244070-A1 | Use of Organic Glucosamine Salts | BIOIBERICA, S.A. (ES) | 2007-10-18 | — | — | US | claimed |
| EP-1781304-A1 | USE OF ORGANIC GLUCOSAMINE SALTS | BIOIBERICA, S.A. (ES) | 2007-05-09 | — | — | EP | claimed |
| WO-2006012951-A1 | USE OF ORGANIC GLUCOSAMINE SALTS | BIOIBERICA, S.A. (ES) | 2006-02-09 | — | — | WO | claimed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| EP-1238669-B1 | Neutrophil function inhibitors which contain glucosamine | DAINICHISEIKA COLOR CHEM (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-6627621-B2 | Neutrophil function inhibitors | DAINICHIESEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2003-09-30 | — | — | US | claimed |
| US-20020128230-A1 | Neutrophil function inhibitors | KOYO CHEMICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | claimed |
| EP-1238669-A2 | Neutrophil function inhibitors which contain glucosamine | Dainichiseika Color & Chemicals Mfg. Co., Ltd. (JP) | 2002-09-11 | — | — | EP | claimed |
| US-20230167474-A1 | Methods for enzymatic production of glucosamine salts and the purification methods thereof | JIANGSU HARVERS BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| CN-113336806-A | Preparation method of glucosamine organic acid salt | 江苏海飞生物科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-111518857-A | Enzyme method for producing glucosamine salt and purification method thereof | 江苏海飞生物科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-6627621-B2 | Neutrophil function inhibitors | DAINICHIESEIKA COLOR & CHEMICALS MFG. CO., LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| WO-2003049696-A2 | GLUCOSAMINE ORGANIC ACID ADDUCTS | CARGILL, INCORPORATED (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20020128230-A1 | Neutrophil function inhibitors | KOYO CHEMICAL CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-1238669-A2 | Neutrophil function inhibitors which contain glucosamine | Dainichiseika Color & Chemicals Mfg. Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | ALDH1A1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.